REGULATORY

Drug Pricing Organization to Price JCR’s Cell Therapy Temcell

October 1, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) agreed on September 30 that the reimbursement price of JCR Pharmaceuticals’ recently approved cell-based therapy will be set by the Drug Pricing Organization as the product has characteristics close to those of pharmaceuticals.…

To read the full story

Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
September 24, 2015
Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015

REGULATORY

MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

TSE’s Growth Market Reform Puts Pressure on Biotechs

By Tatsuya Otsuka

Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…